EUVIMEDEUVIMED entdecken
Crossref

Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention?

Zachary J Prebay, Halle Foss, David Ebbott, Jason Hyman, Michael Li, Paul H Chung

Urology · 2023

DOI: 10.1016/j.urology.2023.01.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urology, 2023. Verfasst von Zachary J Prebay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Hauptthemen laut MEDLINE: Penile Implantation, Penile Prosthesis, Symporters, Urinary Sphincter, Artificial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To understand whether patients taking sodium-glucose co-transporter 2 inhibitors (SGLT2i) would be at a similar risk of genitourinary device infection or failure as patients not taking these medications. METHODS: We queried the TriNetX database for all adult male patients undergoing artificial urinary sphincter (AUS) or inflatable penile prosthesis (IPP) and compared patients taking SGLT2i against those not. Cohorts and outcomes were defined using current procedural terminology and International Classification of Diseases (ICD-10) codes. We used Age, body mass index, diabetes, smoking history and history of prostatectomy to generate propensity score matching. Our primary outcome was need for reintervention after implantation based on current procedural terminology codes. Secondary outcomes included infection rate and overall complication rate based on ICD-10 codes. Analytics were performed via TriNetX which calculated risk ratios. RESULTS: Analyses were run on November 28, 2022. After propensity score matching, there were 319 and 83 patients in each IPP and AUS cohort and comorbidity profiles were similar. Patients with an IPP on an SGLT2i were at a lower risk of overall complication (10.6% vs 16.1%, RR 0.66, P = .049). There was similar rates for AUS and risk of complication and for either implant on risk of infection or reintervention. CONCLUSION: Patients taking SGLT2is may be safely offered urologic implants. Patients taking an SGLT2 had a lower risk of complication for IPP, and there were similar rates of infection and reintervention for both IPP and AUS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Penile ImplantationPenile ProsthesisSymportersUrinary Sphincter, ArtificialAdultHumansMaleGlucoseRetrospective StudiesSodiumSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2

Substanzen

GlucoseSodiumSymportersSodium-Glucose Transporter 2 InhibitorsSLC5A2 protein, humanSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
  • Center for Digital Health and Data Science, Thomas Jefferson University, Philadelphia, PA.
  • Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Electronic address: Paul.Chung@jefferson.edu.

Zitieren

APA

Prebay, Z. J., Foss, H., Ebbott, D., Hyman, J., Li, M., & Chung, P. H. (2023). Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention?. Urology. https://doi.org/10.1016/j.urology.2023.01.032

Vancouver

Prebay ZJ, Foss H, Ebbott D, Hyman J, Li M, Chung PH. Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention?. Urology. 2023. doi:10.1016/j.urology.2023.01.032

BibTeX
@article{Prebay2023,
  author = {Prebay, Zachary J and Foss, Halle and Ebbott, David and Hyman, Jason and Li, Michael and Chung, Paul H},
  title = {Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention?},
  journal = {Urology},
  year = {2023},
  doi = {10.1016/j.urology.2023.01.032}
}
Kostenlos starten →